Atlas Molecular Pharma announces the start of human clinical trial

The Basque company begins the first phase I clinical trial with ATL-001 for the treatment of congenital erythropoietic porphyria (CEP) Atlas Molecular Pharma (Atlas), a spin-off from the CIC bioGUNE research center and led by Óscar Millet and Joaquín Castilla, was founded in 2015 with the aim of developing new pharmacological chaperones for the treatment […]